MedPath

Efficacy of the Apitherapy in the treatment of recalcitrant localized plaque psoriasis and evaluation of Tumor Necrosis Factor-Alpha (TNF-a) serum level: Double blind randomized clinical trial.

Phase 3
Completed
Conditions
ocalized psoriasis
Inflammatory and Immune System - Autoimmune diseases
Localized psoriasis
Skin - Dermatological conditions
Registration Number
ACTRN12613001028796
Lead Sponsor
Faculty of Medicine, Suez Canal University, prof. Atef Elakhras
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
50
Inclusion Criteria

*Patients diagnosed as recalcitrant localized psoriasis.
*Patients aged 18 -60 years.
*Both genders.
*Stopping any topical or systemic treatment for psoriasis during the last 2 months.

Exclusion Criteria

*Patient who had any allergic disorder.
*Patient who had reactions to bee stings.
*Patient who are responding well to conventional treatment.
*Pregnancy and lactation.
*Systemic diseases such as diabetes and cardiac diseases

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis, by assessing Physician Global Assessment (PGA) before and after treatment[To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis at the end of 3 months of treatment];To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis at the end of 3 months of treatment. By assessing with physician global assessment (PGA).[To evaluate the therapeutic potential effect of Bee venom in recalcitrant localized Psoriasis at the end of 3 months of treatment]
Secondary Outcome Measures
NameTimeMethod
To detect the effect of Bee venom on the serum level of Tumor necrosis factor alpha (TNF-a).[To detect the effect of Bee venom on the serum level of Tumor necrosis factor alpha (TNF-a).by measuring serum level of (TNF-a) at the beginning and 12th week of treatment via polystyrene microplate ELISA]
© Copyright 2025. All Rights Reserved by MedPath